In the BioHarmony Drug Report Database

"Preview" Icon

Burosumab

Crysvita (burosumab) is an antibody pharmaceutical. Burosumab was first approved as Crysvita on 2018-02-19. It has been approved in Europe to treat familial hypophosphatemia and familial hypophosphatemic rickets. The pharmaceutical is active against fibroblast growth factor 23.

 

Trade Name

 

Crysvita
 

Common Name

 

burosumab
 

ChEMBL ID

 

CHEMBL3707326
 

Indication

 

familial hypophosphatemia, familial hypophosphatemic rickets
 

Drug Class

 

Monoclonal antibodies: fully human, bone target

Image (chem structure or protein)

Burosumab structure rendering